Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting®
- American Heart Association Scientific Sessions 2022,
Chicago, IL Saturday, November 5, 2022
Poster Presentation at11:00 am Central Time
Title: Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators
Lead Author:Jorge Plutzky , MD, Director, Preventive Cardiology, Brigham and Women’s Hospital
American Association for the Study of Liver Disease , The Liver Meeting®,Washington, DC Monday, November 7, 2022
Poster Presentation at1:00 pm Eastern Time
Title: Effects of a Balanced GLP-1/Glucagon Receptor Dual Agonist on Reduction of Liver Fat and Weight Loss: Results of a Phase 1b Multicenter, Randomized, Double-blind, Placebo-controlled Trial in Patients with Non-alcoholic Fatty Liver Disease
Lead Author:Stephen A. Harrison , MD, Medical Director,Pinnacle Research
A copy of the presentation materials will be accessible on the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Altimmune Investor & Media Contact:
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com
Source: Altimmune, Inc